摘要
目的观察甲磺酸阿帕替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取2016年1月1日-2018年12月31日于菏泽市定陶区人民医院就诊的晚期NSCLC患者90例,采用随机数字表法分为阿帕替尼组和对照组,每组45例。阿帕替尼组给予甲磺酸阿帕替尼治疗,对照组给予多西他赛联合顺铂治疗。比较2组临床疗效、治疗前后肿瘤标志物水平及不良反应。结果2组患者客观缓解率(ORR)比较差异无统计学意义(P>0.05),阿帕替尼组患者疾病控制率(DCR)为88.89%,高于对照组的66.67%(P<0.05)。治疗后,2组患者血清糖类抗原50(CA50)、糖类抗原199(CA199)、糖类抗原125(CA125)、血清癌胚抗原(CEA)水平均低于治疗前(P<0.01),且阿帕替尼组低于对照组(P<0.01)。阿帕替尼组患者不良反应总发生率为24.44%,低于对照组的48.89%(P<0.05)。结论甲磺酸阿帕替尼治疗晚期NSCLC的临床疗效和安全性较传统方案均具有一定优势,可在临床推广使用。
Objective To observe the clinical efficacy and safety of apatinib mesylate in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 90 patients with advanced NSCLC who were treated in Heze Dingtao People’s Hospital from January 1,2016 to December 31,2018 were selected,random number table method was used to divide patients into apatinib group and control group,45 cases in each group.The apatinib group was given apatinib mesylate,and the control group was given docetaxel combined with cisplatin.The clinical efficacy,tumor marker levels before and after treatment and the incidence of adverse reactions were compared between the 2 groups.Results There was no statistically significant difference in objective response rate(ORR)between the two groups(P>0.05).The disease control rate(DCR)of the apatinib group was 88.89%,higher than the control group’s 66.67%(P<0.05).After treatment,the levels of serum carbohydrate antigen 50(CA50),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125),and serum carcinoembryonic antigen(CEA)in the two groups were lower than before treatment(P<0.01),and the apatinib group was lower than the control group(P<0.01).The total incidence of adverse reactions in the apatinib group was 24.44%,which was lower than 48.89%in the control group(P<0.05).Conclusion The clinical efficacy and safety of apatinib in the treatment of advanced NSCLC are better than that of the traditional scheme,which can be widely used in clinical practice.
作者
孔祥训
KONG Xiangxun(Department of Oncology and Hematology,Heze Dingtao People’s Hospital,Shandong Province,Heze 274100,China)
出处
《临床合理用药杂志》
2020年第22期19-21,共3页
Chinese Journal of Clinical Rational Drug Use
